Skin Substitute Payment Reductions: New HCPCS Coding & Reimbursement Rules for 2026

If you work in wound care billing, you've probably already felt the impact of this one. CMS completely restructured how Medicare pays for skin substitutes starting January 1, 2026 — and it's not a minor tweak. We're talking about a nearly 90% reduction in aggregate spending, a flat payment rate replacing the old ASP+6% model, and a new coding framework built around FDA regulatory categories.

Let's walk through what actually changed, why CMS made these moves, and — most importantly — what your practice needs to do right now to stay compliant and protect whatever margin remains. For a deeper dive into the CMS final rule itself, check out our full analysis on Skin Substitute Reimbursement in 2026: CMS Final Rule Explained for Wound Care Practices.

Why Did CMS Cut Skin Substitute Payments So Dramatically?

Here's the short version: Medicare Part B spending on skin substitutes went from $252 million in 2019 to over $10 billion in 2024. That's a nearly 40-fold increase in five years — while patient volume only doubled. CMS concluded that the old ASP+6% payment model was creating perverse incentives: manufacturers could set high list prices, providers could bill generous markups, and the program bore the cost.

So CMS reclassified most skin substitutes as "incident-to supplies" under the Physician Fee Schedule. That single change pulled these products out of the ASP drug-pricing framework and into a flat-rate supply payment model. The result? A single national payment rate of $127.28 per square centimeter for nearly all skin substitute products in 2026, regardless of brand or acquisition cost.

The New FDA-Based Product Categories

CMS now categorizes skin substitutes by their FDA regulatory pathway — not by brand name or clinical indication. This matters because the HCPCS code you bill must match the product's FDA classification. Any mismatch increases audit risk. For compliance guidance around wound care LCDs and documentation, see our resource on Advanced Wound Care LCDs and Compliance.

FDA Category	What It Includes	2026 Payment
361 HCT/Ps (Section 361, PHS Act)	Human cells, tissues, and cellular/tissue-based products — typically wound coverings and dressings	$127.28/sq cm (flat rate)
510(k) Cleared Devices	Devices cleared through FDA's 510(k) process — wound dressings that maintain moisture and protect	$127.28/sq cm (flat rate)
PMA-Approved Devices	Products with Premarket Approval — intended to provide direct therapeutic treatment effects	$127.28/sq cm (flat rate)
351 BLA Biologics (Exception)	Products licensed under Section 351 of PHS Act as biological products	Continues at ASP+6% methodology

 

The key takeaway: Only products with a full Biologics License Application (BLA) under Section 351 keep the old ASP+6% reimbursement. Everything else — which covers the vast majority of skin substitutes used in wound care — drops to the $127.28 flat rate.

HCPCS Code Changes You Need to Know

CMS deleted the low-cost HCPCS codes C5271 through C5278 that were previously used for skin substitute application. Going forward, the high-cost application codes 15271-15278 apply across all settings.

CPT Code	Description	Setting
15271	Application of skin substitute graft to trunk, arms, legs; first 25 sq cm or less wound surface area	All settings
15272	Each additional 25 sq cm, or part thereof (add-on to 15271)	All settings
15275	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, digits; first 25 sq cm or less	All settings
15276	Each additional 25 sq cm, or part thereof (add-on to 15275)	All settings

 

What About Wastage?

This one catches a lot of practices off guard. Under the new rules, you can no longer bill Medicare for any discarded or unused portion of a non-BLA skin substitute product. Reimbursement is limited strictly to the amount actually applied to the patient. If you open a 50 sq cm sheet and only use 30 sq cm, you're billing for 30. The remaining 20 sq cm is your cost to absorb.

Common ICD-10 Codes for Skin Substitute Applications (Connector-Verified)

The diagnosis code must support medical necessity for the wound care procedure and skin substitute application. These codes have been verified through the ICD-10 diagnostic code connector as HIPAA-valid. Proper coding is especially important given the heightened scrutiny CMS is applying to wound care claims. For guidance on handling denials when they happen, see Wound Care Denials: How to Handle Appeals and Resubmissions Effectively.

ICD-10 Code	Description	Common Wound Type
E11.621	Type 2 diabetes mellitus with foot ulcer	Diabetic foot ulcer (most common indication)
L97.519	Non-pressure chronic ulcer of other part of right foot, unspecified severity	Chronic non-healing lower extremity ulcer
L89.310	Pressure ulcer of right buttock, unstageable	Pressure injury requiring graft coverage
I83.029	Varicose veins of left lower extremity with ulcer of unspecified site	Venous stasis ulcer
T81.89XA	Other complications of procedures, NEC, initial encounter	Post-surgical wound dehiscence

 

What Your Practice Should Do Now

These changes are already in effect, so the time for preparation has passed — it's now about execution. Here's what we recommend for wound care practices navigating this new landscape. Making sure your foundational billing and coding processes for skin substitute grafts.

• Product-to-code mapping: Audit your product inventory against FDA classifications. Every skin substitute you stock needs to be mapped to its correct FDA category (361 HCT/P, 510(k), PMA, or 351 BLA) to determine the right HCPCS code
• Financial review: Conduct a margin analysis comparing your acquisition cost per sq cm against the $127.28 reimbursement rate. Products that cost more than $127.28/sq cm to acquire are now margin-negative under Medicare
• Documentation update: Update documentation templates to capture the exact wound surface area measured and the exact amount of product applied — no more billing for wastage
• Coding training: Train your coding team on the 15271-15278 code set and the deletion of C5271-C5278. Any claim submitted with deleted codes will be rejected outright
• LCD coverage check: Verify whether each product you use retains separate LCD coverage or falls under the withdrawn LCDs — CMS withdrew several prominent skin substitute LCDs in 2025-2026

Frequently Asked Questions

Q: How much did CMS reduce skin substitute payments for 2026?

A: CMS estimates the new payment methodology will reduce Medicare skin substitute spending by approximately $19.6 billion in 2026 — a nearly 90% reduction from prior spending levels. Most products now receive a flat rate of $127.28 per square centimeter, replacing the previous ASP+6% model that allowed variable, brand-specific pricing.

Q: Which skin substitute products still get paid under the old ASP+6% model?

A: Only products licensed under Section 351 of the Public Health Service Act with a full Biologics License Application (BLA) continue to be paid under the ASP+6% methodology. All other skin substitutes — including 361 HCT/Ps, 510(k)-cleared devices, and PMA-approved devices — are now paid as incident-to supplies at the flat $127.28/sq cm rate.

Q: Can I still bill Medicare for unused or wasted skin substitute product?

A: No. Under the 2026 rules, reimbursement is limited strictly to the portion of the product actually applied to the patient. Discarded or unused skin substitute material is no longer separately billable to Medicare. This applies to all non-BLA products classified as incident-to supplies.

Q: What happened to HCPCS codes C5271 through C5278?

A: CMS deleted the C5271-C5278 code series, which were previously used for low-cost skin substitute applications. Going forward, all skin substitute graft applications are billed using CPT codes 15271-15278 regardless of the clinical setting. Any claims submitted with deleted C-codes will be rejected.

Q: How should wound care practices adjust to maintain financial viability?

A: Practices should map every product to its FDA classification, conduct margin analysis against the $127.28 rate, negotiate lower acquisition costs with suppliers, shift to products with favorable margins, update documentation to capture exact application area, and consider whether 351 BLA products offer better reimbursement for appropriate clinical scenarios.